Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Wave Life Sciences Q3 2026 Results: Net Loss of $61.9M, Loss Widens

Wave Life Sciences reported total assets of $507.9 million as of September 30, 2026, a decrease from $638.5 million at year-end 2025, primarily driven by a reduction in cash and cash equivalents. The company transitioned a significant portion of its liquidity into marketable securities and reported 197,228,968 shares of common stock outstanding as of October 21, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue13.27.6
Profit before tax-61.9-53.9
Net income-61.9-53.9
EPS (diluted, $ a share)$-0.30$-0.32

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+72.9%
Source

10-Q filed with the SEC, NASDAQ: WVE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Wave Life Sciences, Inc.: key numbers

Share price
$2.87Close, Nov 16
Market cap
$566M
Shares outstanding
197.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Wave Life Sciences, Inc.

All →
7:37 AM ET 8-K
Financial Results

Wave Life Sciences Financial Results

Wave Life Sciences reported Q3 2026 financial results, highlighting a cash position of $431 million and an expected runway into Q3 2028. The company is advancing its RNA editing and siRNA clinical programs, including planning for a registrational trial of WVE-006 in AATD and ongoing Phase 2a dosing for WVE-007 in obesity.

Term
Q3 2026

“Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial.”

Paul Bolno, MD, MBA, President and Chief Executive Officer

“Importantly, our PRISM platform and chemistry continue to demonstrate unique value both within our own pipeline and beyond. The advancement of a development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class siRNA with SpiNA design, with three additional collaboration programs still advancing.”

Paul Bolno, MD, MBA, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.